1.New Strategy for anti-HBV therapy: blocking P-8 interaction.
Chinese Journal of Virology 2014;30(6):713-720
Clinically being applied treatment against chronic hepatitis has three limitations: low response rates, severe adverse effects and a high rate of drug resistance. Hence, novel targets for antiviral therapy need to be developed so as to provide an armory of different strategies. During the replication of hepatitis B virus, the interaction of viral polymerase (P protein, also called P) and epsilonRNA is indispensable for the initiation of reverse transcription via protein priming and the pregenome RNA (pgRNA) packaging. Three strategies are currently developed for blocking P-epsilon interaction: heat shock protein inhibitors, epsilonaptamers and chemical compounds for blocking formation of P-epsilon complex. Previously, our group has for the first time worldwide in vitro screened several aptamers, which are able to interfere with the P-epsilon interaction. A strong inhibition against HBV was observed in vitro and in vivo experiments, respectively. In conclusion, the so far developed chemicals suppressing the P-epsilon interaction may bypass or overcome the viral resistance problems during clinic treatment and represent a highly attractive option for therapeutic intervention.
Animals
;
Gene Expression Regulation, Viral
;
Gene Products, pol
;
antagonists & inhibitors
;
genetics
;
metabolism
;
Hepatitis B
;
therapy
;
virology
;
Hepatitis B virus
;
enzymology
;
genetics
;
physiology
;
Humans
;
RNA, Viral
;
genetics
;
metabolism
;
Virus Replication
2.Cell proteins that potentially interact with HBV polymerase were identified by co-immunoprecipitation-based LC-MS/MS identification and IPA.
Meng-ting LING ; Jun-yuan GONG ; Jun-wu LI ; Tian-hong ZHOU
Chinese Journal of Virology 2014;30(6):636-644
Hepatitis B virus (HBV) is a major cause of chronic liver disease, and frequently results in hepatitis, cirrhosis, and ultimately hepatocellular carcinoma. HBV polymerase (Pol) is an essential viral protein that is important for HBV replication and might be involved in the development of hepatocellular carcinoma. Protein-protein interactions appears to be crucial for its role. The aim of this study was to screen and identify the proteins that interact with Pol using a co-immunoprecipitation-based LC-MS/MS identification technique. The HBV Pol gene was amplified by polymerase chain reaction (PCR) and cloned into pCDNA3.1(+). The recombinant plasmid pCDNA3. 1(+)-Pol-flag was transfected into HeLa cells. Liquid chromatography and tandem mass spectrometry (LC-MS/MS) identified 45 proteins that co-immunoprecipitated with flag-tagged HBV Pol. Eleven of these have previously been reported as proteins that interact with HBV Pol. A proof-of-concept-based Ingenuity Pathway Analysis (IPA, www.ingenuity.com) was used to characterize the functions and pathways of these 45 identified proteins and HBV Pol. Among these proteins, four proteins may play a role in three major molecular cellular networks, and are therefore worthy of further investigation.
Cell Line, Tumor
;
Chromatography, Liquid
;
methods
;
Gene Products, pol
;
chemistry
;
genetics
;
metabolism
;
Hepatitis B
;
genetics
;
metabolism
;
virology
;
Hepatitis B virus
;
chemistry
;
enzymology
;
genetics
;
Humans
;
Immunoprecipitation
;
methods
;
Protein Interaction Maps
;
Software
;
Tandem Mass Spectrometry
;
methods
3.From DCPD to NTCP: The long journey towards identifying a functional hepatitis B virus receptor.
Clinical and Molecular Hepatology 2015;21(3):193-199
Hepatitis B virus (HBV) is the prototype of hepatotropic DNA viruses (hepadnaviruses) infecting a wide range of human and non-human hosts. Previous studies with duck hepatitis B virus (DHBV) identified duck carboxypeptidase D (dCPD) as a host specific binding partner for full-length large envelope protein, and p120 as a binding partner for several truncated versions of the large envelope protein. p120 is the P protein of duck glycine decarboxylase (dGLDC) with restricted expression in DHBV infectible tissues. Several lines of evidence suggest the importance of dCPD, and especially p120, in productive DHBV infection, although neither dCPD nor p120 cDNA could confer susceptibility to DHBV infection in any cell line. Recently, sodium taurocholate cotransporting polypeptide (NTCP) has been identified as a binding partner for the N-terminus of HBV large envelope protein. Importantly, knock down and reconstitution experiments unequivocally demonstrated that NTCP is both necessary and sufficient for in vitro infection by HBV and hepatitis delta virus (HDV), an RNA virus using HBV envelope proteins for its transmission. What remains unclear is whether NTCP is the major HBV receptor in vivo. The fact that some HBV patients are homozygous with an NTCP mutation known to abolish its receptor function suggests the existence of NTCP-independent pathways of HBV entry. Also, NTCP very likely mediates just one step of the HBV entry process, with additional co-factors for productive HBV infection still to be discovered. NTCP offers a novel therapeutic target for the control of chronic HBV infection.
Animals
;
Carboxypeptidases/genetics/*metabolism
;
Gene Products, pol/genetics/metabolism
;
Heparan Sulfate Proteoglycans/metabolism
;
Hepatitis B virus/*physiology
;
Hepatocytes/metabolism/virology
;
Organic Anion Transporters, Sodium-Dependent/antagonists & inhibitors/genetics/metabolism
;
RNA Interference
;
Symporters/antagonists & inhibitors/genetics/metabolism
;
Viral Envelope Proteins/metabolism
;
Virus Internalization
4.Establishment and application of a high-throughput screening assay for premature activation of HIV-1 precursors.
Quan ZHANG ; Xiao-yu LI ; Zhen-long LIU ; Ping-ping JIA ; Xiao-lu WEI ; Li-xun ZHAO ; Jian-dong JIANG ; Shan CEN
Acta Pharmaceutica Sinica 2010;45(2):247-252
Strict regulation of HIV-1 PR function is critical for efficient production of mature viral particles. During viral protein expression and viral assembly, HIV-1 PR located within Gag-Pol precursor must be inactive to prevent premature cytoplasmic processing of the viral Gag and Gag-Pol precursors. Premature activation of HIV-1 precursors leads to major defects in viral assembly and production of viral particles. A cell-level premature activation of HIV-1 precursors assay using bioluminescence resonance energy transfer (BRET) was established. Three thousand compounds were screened to evaluate this assay. The results showed that the assay is sensitive, specific and stable (Z' factor is 0.905).
Anti-HIV Agents
;
pharmacology
;
Benzoxazines
;
pharmacology
;
Bioluminescence Resonance Energy Transfer Techniques
;
methods
;
Fusion Proteins, gag-pol
;
genetics
;
metabolism
;
HEK293 Cells
;
HIV Protease
;
metabolism
;
physiology
;
HIV-1
;
enzymology
;
High-Throughput Screening Assays
;
methods
;
Humans
;
Plasmids
;
genetics
;
Protein Precursors
;
metabolism
;
physiology
;
Pyridazines
;
pharmacology
;
Transfection
;
Virion
;
growth & development
;
Virus Assembly
;
gag Gene Products, Human Immunodeficiency Virus
;
genetics
;
metabolism
5.Human Monoclonal Antibody Inhibiting Reverse Transcriptase Activity of Hepatitis B Virus Polymerase Protein.
Sung Jae PARK ; Sang Yong SEOL ; Sam Ryong JEE ; Eun Taik PARK ; Youn Jae LEE ; Sang Hyuk LEE ; Jung Myung CHUNG ; Hyun Dae CHO ; Young Ju JEONG ; In Hak CHOI ; Sae Gwang PARK
The Korean Journal of Gastroenterology 2007;49(2):85-92
BACKGROUND/AIMS: To develop a novel treatment method for hepatitis B virus (HBV) infection, we aimed to make a human monoclonal antibody inhibiting reverse transcriptase (RT) activity of P protein which was important in HBV replication by using phage display technique. Therefore, we analysed the usability of human monoclonal antibody as a protein based gene therapy. METHODS: Reverse transcriptase/polymerase (RT/POL) functional motif of P protein of HBV was cloned in pMAL-c vector and expressed as maltose binding fusion protein form. The RT/POL recombinant protein (pMRT/POL) was purified by amylose resin column. Using human single chain Fv phage antibody library with 1.1x10(10) size, human antibody against pMRT/POL was selected with BIAcore panning. Selected antibody fragments were analyzed for the activity of RT inhibition. Finally, they were analyzed for the affinity with BIAcore and the complementarity determining regions with nucleotide sequencing. RESULTS: pMRT/POL recombinant protein expressed in E. coli showed RT activity, 1microgram of recombinant protein had an activity equivalent to 5 unit of MMLV RT. By BIAcore panning, we could select 3 clones; POL-A5, POL-B8 and POL-B12. Each clone's RT inhibiting activity were 52-82%, affinity against antigen were 8.15x10(-8) M to 1.75x10(-6) M. CONCLUSIONS: Human monoclonal antibodies produced in this study showed low affinity, but efficiently inhibited the activity of RT in vitro. If POL-A5, POL-B8, and POL-B12 can be converted to intracellular antibody form, it can be used for protein-based gene therapy by inhibiting the replication through the neutralization of polymerase protein of HBV.
Antibodies, Monoclonal/biosynthesis/genetics/*pharmacology
;
Complementarity Determining Regions/chemistry
;
Gene Products, pol/*antagonists & inhibitors/genetics/immunology
;
Genetic Vectors
;
Hepatitis B virus/enzymology/genetics
;
Humans
;
Peptide Library
;
RNA-Directed DNA Polymerase/genetics/*immunology
;
Recombinant Fusion Proteins/biosynthesis/genetics
;
Reverse Transcriptase Inhibitors/chemistry/metabolism/*pharmacology